CTOs on the Move

DTI Dental Technologies Inc.

www.dtidental.com

 
DTI Dental Technologies Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Dublin, CA. To find more information about DTI Dental Technologies Inc., please visit www.dtidental.com
  • Number of Employees: 0-25
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

Davids Productions

Davids Productions is a Montville, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

medSage Technologies LLC

medSage Technologies LLC is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Pittsburgh, PA. To find more information about medSage Technologies LLC, please visit www.medsagetechnologies.com

Emerald Heights

Emerald Heights, sponsored by Emerald Communities, is a nonprofit 501(c)(3) senior housing and service organization that provides its residents programs to cultivate culture, vitality and independence. The community is a Type A Continuing Care Retirement Community (CCRC) that accommodates residents`changing needs throughout the aging process. Situated on 38 acres in the Education Hill area of Redmond, Wash., just 17 miles northeast of Seattle, Emerald Heights is an amenity-rich and resort-style senior living community, plus an assisted living facility and a Medicare-certified skilled nursing health center. The campus opened in 1992 to provide housing and service to people ages 55 and older in the aspects of independent, assisted living and skilled nursing.

Accord BioPharma

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.

Circadiance

Circadiance LLC is a Export, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.